

March 2, 2016

News Release

Company: Olympus Corporation
Representative Director, President: Hiroyuki Sasa
(Code: 7733, First Section, Tokyo Stock Exchange)
Contact: Tetsuo Hyakutake, General Manager, Public Relations and IR Office

Notice of Agreements with the U.S. Government

Olympus Corporation hereby announces that certain of its subsidiaries have entered into agreements with the U.S. Department of Justice (“DOJ”) concerning a matter relating to the U.S. Anti-Kickback Statute and U.S. False Claims Act, announced on 6 February 2015 by the news release titled as “Notice of Investigation by the U.S. Department of Justice against Our Subsidiary,” and a matter relating to the U.S. Foreign Corrupt Practices Act, announced on 6 August 2015 by the news release titled as “Notice of Recognition of Extraordinary Loss Due to the Investigation by the U.S. Department of Justice Against Subsidiaries Relating to the Foreign Corrupt Practices Act”.

I. Agreement Concerning the U.S. Anti-Kickback Statute and U.S. False Claims Act

1. Background

The DOJ investigated Olympus Corporation of the Americas (“OCA”) for conduct raising concerns under the U.S. Anti-Kickback Statute and U.S. False Claims Act by OCA’s medical business in the United States between 2006 and 2011. In particular, the DOJ examined the practices in the medical business of providing grants, other payments, and gifts or loans of Olympus equipment to health care professionals and health care institutions.

2. Agreements

On February 29, 2016, OCA entered into a Deferred Prosecution Agreement with the DOJ in connection with this matter. On February 29, 2016, OCA also entered into a Civil Settlement Agreement with the DOJ in connection with this matter. Pursuant to these agreements, OCA will pay to the U.S. government U.S. \$612 million (approximately 70.4 billion yen) in criminal penalties and civil fines as well as approximately U.S. \$11.2 million (approximately 1.3 billion yen) in interest. On February 29, 2016, OCA also entered into a Corporate Integrity Agreement with the Office of Inspector General of the U.S. Department of Health and Human Services in connection with this matter. Under these agreements, OCA has agreed to make various improvements to its compliance program.

3. Financial Impact and Future Outlook

The criminal penalties and civil fines have been fully reserved for under the line item “Loss related to the U.S. Anti-kickback Act” in the fiscal year ended March 2015 and the third quarter of the fiscal year ending March 2016. We currently anticipate recording of interest as an extraordinary loss in the fiscal year ending March 2016.

There will be no revision to our forecast of consolidated financial results for the fiscal year ending March 2016 on account of this matter.

II. Agreement Concerning the U.S. Foreign Corrupt Practices Act

1. Background

Beginning in October 2011, the DOJ conducted an investigation into alleged violations of the U.S. Foreign Corrupt Practices Act by the medical business of Olympus Latin America, Inc. (“OLA”), an indirect U.S. subsidiary of Olympus Corporation, and Olympus Optical do Brasil, Ltda., a Brazilian subsidiary of OLA (“OBL”). The DOJ’s investigation included OLA’s and OBL’s alleged practices of giving such things as payments or free or discounted equipment to health care professionals.

2. Agreement

On February 29, 2016, OLA and certain of Olympus Corporation’s other subsidiaries, including OCA, entered into a Deferred Prosecution Agreement with the DOJ in connection with this matter. Pursuant to this agreement, OLA will pay to the U.S. government a U.S. \$22.8 million (approximately 2.6 billion yen) criminal penalty, and has agreed to make various improvements to its compliance program.

3. Financial Impact and Future Outlook

As the amounts in question were fully reserved, the signing of the agreement has no impact on Olympus Corporation’s consolidated results.

End